Cayman B7-H4 (human, recombinant)

B7-H4 is a glycoprotein linked to the cell membrane via glycosylphosphatidylinositol (GPI) and a member of the B7-CD28 immune checkpoint protein family. It is composed of an extracellular domain containing immunoglobulin (Ig) variable (IgV) and Ig constant (IgC) domains with several cysteine residues and N-glycosylation sites.^, B7-H4 is found on T cells, B cells, natural killer (NK) cells, dendritic cells, monocytes, and tumor cells, and B7-H4 mRNA is expressed in non-lymphoid tissues such as the lungs, testis, and pancreas.^,, The expression of B7-H4 is induced by inflammatory mediators and cytokines, and it acts as a co-stimulatory molecule to promote regulatory T cell development and inhibit T cell activation, cell cycle progression, proliferation, and cytokine production.^, VTCN1 is overexpressed in a variety of cancers, including breast and ovarian cancers, and the levels of expression correlate with lymph node metastasis, cancer progression, and mortality.^, siRNA knockdown of VTCN1, the gene encoding B7-H4, decreases proliferation and migration of pancreatic cancer cells in vitro. Knockout of VTCN1 in mice reduces lung metastasis and increases survival in a metastatic breast cancer mouse xenograft model. Cayman’s B7-H4 (human, recombinant) protein can be used for cell-based assay applications. This protein is a disulfide-linked homodimer. The reduced monomer, comprised of B7-H4 (amino acids 29-258) fused to human IgG1 Fc at its C-terminus, consists of 471 amino acids and has a calculated molecular weight of 52.3 kDa. As a result of glycosylation, the monomer migrates at approximately 66 to 76 kDa by SDS-PAGE under reducing conditions.

WARNING This product is not for human or veterinary use.